Stallergenes Greer has teamed up with Aptar Pharma to develop a connected device and companion mobile app for the delivery of its allergen immunotherapy (AIT) treatments.
According to UK-based healthcare company, non-adherence to an AIT schedule and premature discontinuation of treatment are considered as a challenge in its management.
Under the partnership, the two companies will develop an advanced and easy-to-use connected device, leveraging Aptar Pharma’s Cohero digital health platform.
Aptar Pharma global digital healthcare systems vice president Sai Shankar said: “We are pleased to combine Aptar Pharma’s Digital Health ecosystem with Stallergenes Greer’s knowledge and leading position in AIT to further improve the treatment journey of patients who suffer from allergies.”
Aptar Pharma’s digital health business will develop the new connected device, which is expected to improve dose compliance and adherence, and optimise treatment outcomes.
The device will be initially commercialised in France from next year, with plans to roll out in Stallergenes Greer’s markets.
Stallergenes Greer France, Belgium and Luxembourg general manager Dominique Pezziardi said: “This exclusive partnership with Aptar Pharma demonstrates the intensification of Stallergenes Greer’s investments in innovation to provide a large range of precise personalised allergen immunotherapy options adapted to the individual needs and lifestyle of patients.
“Stallergenes Greer is well advanced on its digital transformation journey and will continue to develop its e-health offering for the benefit of all stakeholders.”
Aptar Pharma is engaged in designing and manufacturing a range of drug delivery, consumer product dispensing and active material science solutions.
The partnership is part of Aptar’s efforts to expand in the field of digital therapeutics. The company’s digital healthcare plans include expansion into therapeutic areas such as respiratory, pain, CNS, allergy, oncology, and diabetes.
Earlier this year, Aptar has entered into a share purchase agreement to acquire a controlling stake in digital therapeutics developer Voluntis.
